Sushil Patel - 02 Dec 2025 Form 4 Insider Report for Replimune Group, Inc. (REPL)

Role
Chief Executive Officer, Director
Signature
/s/ Shawn Glidden, attorney-in-fact
Issuer symbol
REPL
Transactions as of
02 Dec 2025
Net transactions value
-$111,300
Form type
4
Filing time
04 Dec 2025, 16:30:14 UTC
Previous filing
30 Jun 2025
Next filing
19 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Patel Sushil Chief Executive Officer, Director C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, SUITE 303, WOBURN /s/ Shawn Glidden, attorney-in-fact 04 Dec 2025 0001860609

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REPL Common Stock Sale $111,300 -10,000 -2.9% $11.13 333,576 02 Dec 2025 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 2, 2025, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
F2 The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.00 to $11.26. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3 Following the sales reported on this Form 4, the reporting person continues to beneficially own 333,576 shares of the Issuer's common stock, including restricted stock units. The reporting person also holds options to acquire an aggregate of 753,750 shares of the Issuer's common stock, 331,353 of which are exercisable as of the date hereof.